 Skye Bioscience inc OTCQB:SKYE said completion of the production of its Phase 1 drug has been delayed to the beginning of September 2022 due to a now resolved cyber-attack and planned maintenance shutdown at its contract manufacturer CMO. Skye said it now expects to initiate enrollment of its Phase 1 clinical study in Q4 2022, report preliminary topline data in early Q1 2023, and report final data in Q2 2023. 